Product
DCR-PHXC
Aliases
Nedosiran
3 clinical trials
7 indications
Indication
Primary Hyperoxaluria Type 1Indication
Primary Hyperoxaluria Type 2Indication
Kidney DiseasesIndication
Urologic DiseasesIndication
Genetic DiseaseIndication
Primary Hyperoxaluria Type 3Indication
End-Stage Renal DiseaseClinical trial
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary HyperoxaluriaStatus: , Estimated PCD: 2030-04-01
Clinical trial
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without DialysisStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary HyperoxaluriaStatus: Completed, Estimated PCD: 2021-06-21